Dipeptidyl peptidase‐4 inhibitors and angioedema: a class effect?
Copyright policy )Dipeptidyl peptidase‐4 inhibitors and angioedema: a class effect?
AbstractBackgroundDipeptidyl peptidase‐4 (DPP‐4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs.Case reportWe report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP‐4 inhibitor, alogliptin.DiscussionOur case suggests that there is a difference in the risk of angioedema among DPP‐4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP‐4 inhibitors is warranted.
- Keio University Japan
Male, Vildagliptin, Dipeptidyl-Peptidase IV Inhibitors, Pyrrolidines, Drug Substitution, Adamantane, Diabetes Mellitus, Type 2, Piperidines, Nitriles, Humans, Angioedema, Uracil, Aged
Male, Vildagliptin, Dipeptidyl-Peptidase IV Inhibitors, Pyrrolidines, Drug Substitution, Adamantane, Diabetes Mellitus, Type 2, Piperidines, Nitriles, Humans, Angioedema, Uracil, Aged
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).19 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!